Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Pharmaceuticals will not advance clinical trials of a treatment for Type 1 diabetes after efficacy data failed to support further clinical advancement.

Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Vertex Pharmaceuticals is flexing its innovation muscles beyond its cystic fibrosis stronghold, charging into new territories ...

5000-S8 Schedule 8 - Canada Pension Plan Contributions and Overpayment (for all except QC) 2025-01-21 5000-S7 Schedule 7 - RRSP, PRPP, and SPP Contributions and Transfers, and HBP and LLP Activities ...